The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPjsc Tatneft Regulatory News (ATAD)

  • This share is currently suspended. It was suspended at a price of 2.35

Share Price Information for Pjsc Tatneft (ATAD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.35
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 2.35
ATAD Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Yearly Report

9 Sep 2013 07:48

RNS Number : 4956N
OAO Tatneft
09 September 2013
 



Tatneft published its IFRS consolidated interim condensed financial information for the three and six months ended 30 June 2013

 

9 September 2013

 

OAO Tatneft (the "Company") published today on its web-site (http://www.tatneft.ru/eng) the unaudited consolidated interim condensed financial information for the three and six months ended 30 June 2013 prepared in accordance with International Financial Reporting Standards ("IFRS") (the "Financial Statements") and related Management Discussion and Analysis of Results of Operations (the "MD&A").

 

Selected financial highlights below are based on the respective IFRS financial statements of the Company. These highlights do not replace the Financial Statements or the MD&A and all interested persons are encouraged to read these documents for full understanding of three and six months ended 30 June 2013 IFRS results.

 

Key financial highlights:

 

 

 

Three months ended 30 June:

Six months ended 30 June:

2013

2012

Change, %

2013

2012

Change, %

Sales and other operating revenues, net (RR million)

104 696

95 884

9%

211 250

207 143

2%

Profit attributable to Group shareholders

(RR million)

14 935

4 538

229%

31 909

31 903

0%

EBITDA* (RR million)

26 010

18 290

42%

54 988

55 682

-1%

* Information on EBITDA calculation is set out in the MD&A.

 

30 June

2013

31 December 2012

Change,

%

Total assets (RR million)

656 140

630 607

4%

Total liabilities (RR million)

195 907

184 374

6%

Total shareholders' equity (RR million)

460 233

446 233

3%

 

The Company's representatives will discuss the IFRS financial highlights for the three and six months ended 30 June 2013 on a conference call on 10 September 2013 at 16:00 Moscow time, 13:00 UK time.

 

To participate in the conference call, please dial the any of the following numbers** using Conference ID # 55045883:

 

United Kingdom: +44 1452 555 566 (standard international)

United Kingdom: 0844 493 3800 (local call)

United Kingdom: 0800 694 0257 (free call from within the country)

USA: (866) 966 9439 (free call from within the country)

USA: (631) 510 7498 (local call)

Singapore: 8001 203 988 (free call from within the country)

Russia: 8108 002 097 2044 (free call from within the country)

 

The conference call replay will be available upon completion of the call until 23 September 2013 by dialing** +44 1452 55 0000 (international dial-in) or 0800 953 1533 (free call dial-in from within the UK), (866) 247 4222 (free call dial-in from within the USA), using conference ID # 55045883.

 

** OAO Tatneft shall not be liable for inability to use any of the free numbers.

 

Forward-looking statements: These materials contain statements about future events and expectations that are forward-looking in nature. Any statement in these materials that is not a statement of historical fact is a forward-looking statement that involves known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements expressed or implied by such forward-looking statements to differ. OAO Tatneft assumes no obligations to update the forward-looking statements contained herein to reflect actual results, changes in assumptions or changes in factors affecting these statements.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACSEAKNNELKDEEF
Date   Source Headline
29th Dec 202311:41 amRNSEGM Approves Dividends for 9m 2023
21st Nov 20233:18 pmRNSTatneft EGM to approve 9m 2023 dividend
29th Sep 20239:42 amRNSTatneft EGM approves 6m 2023 dividend
15th Aug 20233:21 pmRNSBoard of Directors 1H 2023 div and EGM decisions
30th Jun 20232:44 pmRNSPJSC Tatneft AGM Results
19th Jun 20238:33 amRNSNotice of AGM
27th Apr 202312:20 pmRNSAGM Notice and Dividend Recommendation
30th Mar 20232:15 pmRNSAcquisition of business from Nokian Tyres plc
20th Mar 20237:00 amRNSTatneft's Annual IFRS and Directors' Report
28th Dec 20227:00 amRNSResult of EGM
16th Nov 20227:24 amRNSBoard Recommends Dividends for 9m2022
28th Oct 20224:16 pmRNSTatneft to acquire Russian assets of Nokian Tyres
23rd Sep 202210:09 amRNSTatneft EGM Approves Dividends for 1H2022
30th Aug 20227:00 amRNSTatneft publishes IFRS results for 1H2022
16th Aug 20229:52 amRNSBoard convenes EGM and recommends dividends 1H2022
9th Aug 202211:42 amRNSNew Legal Regime for ADR Holders
24th Jun 20224:35 pmRNSResult of AGM
15th Jun 20223:29 pmRNSPayments to Governments Report 2021
31st May 20229:45 amRNSStatement regarding 1Q 2022 IFRS accounts
23rd May 20222:40 pmRNSBoard Recommends Dividends
17th May 202210:32 amRNSTatneft Obtained Permit to Continue ADR Program
16th May 20228:46 amRNSTatneft Sells Tire Business
29th Apr 20222:04 pmRNSBoard Reapproves Nominations to the Board
27th Apr 202212:28 pmRNSNotice to ADR Holders
25th Apr 20225:24 pmRNSBoard Approves AGM Agenda, Related Issues
19th Apr 202211:10 amRNSLaw Affecting ADR Program - Correction
19th Apr 20229:22 amRNSLaw Affecting ADR Program
1st Apr 20223:10 pmRNSDraft Law; Rating Withdrawal
15th Mar 20228:31 amRNSAnnual Financial Report
14th Mar 202210:06 amRNSStatement regarding Ratings
10th Mar 20223:18 pmRNSBoard Approves Nominations
2nd Mar 20224:41 pmRNSSecond Price Monitoring Extn
2nd Mar 20224:36 pmRNSPrice Monitoring Extension
1st Mar 20224:43 pmRNSSecond Price Monitoring Extn
1st Mar 20224:37 pmRNSPrice Monitoring Extension
28th Feb 20224:41 pmRNSSecond Price Monitoring Extn
28th Feb 20224:37 pmRNSPrice Monitoring Extension
30th Dec 20211:34 pmRNSResult of EGM - Dividends
20th Dec 20219:26 amRNSNew Committee of the Board
30th Nov 202112:35 pmRNSPresentation to Investors
29th Nov 20217:32 amRNS3rd Quarter Results
23rd Nov 20218:03 amRNSBoard Recommends 3Q Dividends
1st Oct 202110:05 amRNSDividend Declaration
27th Aug 20217:25 amRNSHalf-year Report
26th Aug 202110:19 amRNSBoard convenes EGM, recommends dividends
1st Jul 20217:00 amRNSFirst Board Meeting and Board Committees Election
30th Jun 20215:15 pmRNSPayments to Governments Report
25th Jun 20215:10 pmRNSResult of AGM
9th Jun 20212:37 pmRNSAcquisition of EkoPet
4th Jun 20217:30 amRNS1st Quarter Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.